Bristol-Myers Squibb Gets Thumbs-Up on Transplant Drug

Xconomy New York — 

The FDA approved belatacept (Nulojix), a new drug from Bristol-Myers Squibb (NYSE: BMY) to prevent the rejection of transplanted kidneys, according to a press release. The drug was approved to be given by infusion, along with other anti-rejection agents such as corticosteroids. It is the first new drug in a decade for kidney-transplant patients—likely a factor in the agency’s decision to approve it, despite concerns of side effects such as a raised risk of developing certain cancers.